RLAY
Relay Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.03 / 10
Netural
Analyst consensus is 100% buy/strong‑buy, yet historical win rates range 0‑50%, indicating limited reliability. Fund‑flow scores 7.19/10 with positive small/medium/large inflows but a negative overall trend, reflecting solid but cautious capital interest.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
25%
Buy
75%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-13
InstitutionGuggenheim
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for RLAY?
- RLAY holds a Bearish analyst rating, with 75% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.03/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
